October 20, 2020

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

“Strides receives USFDA approval for Ethacrynic Acid Tablets”

Thanks & Regards,
For Strides Pharma Science Limited,

Manjula Ramamurthy
Company Secretary

Encl. As above
October 20, 2020

Strides receives USFDA approval for
Ethacrynic Acid Tablets

To be marketed by Strides Pharma Inc. in the US market

Bengaluru, October 20, 2020 – Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Ethacrynic Acid Tablets USP, 25 mg from the United States Food & Drug Administration (USFDA). The product is a generic version of Edecrin® Tablets, 25 mg, of Bausch Health Americas, Inc.

According to IQVIA MAT August 2020 data, the US market for Ethacrynic Acid Tablets USP, 25 mg is approximately US$ 14 Mn. The product will be manufactured at the company’s flagship facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 126 cumulative ANDA filings with USFDA of which 92 ANDAs have been approved and 34 are pending approval.

About Ethacrynic Acid Tablets
Ethacrynic acid is in a class of medications called diuretics ('water pills'). It is used to treat edema (excess fluid held in body tissues) in adults and children caused by medical problems such as cancer, heart, kidney, or liver disease.

About Strides
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an ‘in Africa for Africa’ strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>Corporate Communication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Badree Komandur</strong>&lt;br&gt;Executive Director – Finance &amp; Group CFO&lt;br&gt;+91 80 6784 0747</td>
<td><strong>Usha Iyer:</strong> +91 9987444106&lt;br&gt;Email: <a href="mailto:usha.iyer@strides.com">usha.iyer@strides.com</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Investor Relations</strong></th>
<th><strong>PR Consultancy</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sandeep Baid:</strong> +91 80 6784 0791&lt;br&gt;Email: <a href="mailto:Sandeep.baid@strides.com">Sandeep.baid@strides.com</a></td>
<td><strong>Fortuna PR</strong>&lt;br&gt;K Srinivas Reddy: +91 90005 27213&lt;br&gt;<a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a>&lt;br&gt;K Priya: +91 95354 25418&lt;br&gt;<a href="mailto:priya@fortunapr.com">priya@fortunapr.com</a></td>
</tr>
<tr>
<td><strong>Strides Pharma Science Limited</strong></td>
<td></td>
</tr>
<tr>
<td>----------------------------------</td>
<td></td>
</tr>
<tr>
<td>CIN: L24230MH1990PLC057062</td>
<td></td>
</tr>
<tr>
<td>Regd. Office: 201, 'Devavrata', Sector - 17, Vashi, Navi Mumbai - 400 703</td>
<td></td>
</tr>
<tr>
<td>Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560 076</td>
<td></td>
</tr>
</tbody>
</table>